James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
James P. Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared a post on LinkedIn:
“The findings from this trial set the stage for larger clinical studies designed to evaluate how combining vitamin D analogs with chemotherapy or other cancer therapies impacts survival outcomes.
In addition, future work is needed to test whether baseline vitamin D receptor expression can serve as a reliable biomarker of patient responses to combination therapies, including vitamin D analogs.
‘This study is an important step forward for the use of a vitamin D analog as a stromal remodeling therapy that can overcome therapeutic resistance in pancreatic,’ says Perez.
‘It was built upon foundational basic research at the Salk Institute, validates those preclinical findings in patients, and provides a road map for future studies that could someday establish a new treatment standard.'”
Stay updated with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026